Table 7 Initial antibiotics treatment and clinical outcomes of all patients hospitalized with community-acquired pneumonia (CAP) and patients with severe CAP

 Nonantipseudomonas β-lactams

37 (58.7)

15 (48.4)

.38

14 (56)

12 (48)

.57

 Antipseudomonas β-lactams

15 (23.8)

12 (38.7)

.13

8 (32)

10 (40)

.56

 Macrolide (M)

35 (55.6)

10 (32.3)

.03*

16 (64)

7 (28)

.01*

 Quinolone (Q)

10 (15.9)

6 (19.3)

.67

2 (8)

5 (20)

.42

 Combination therapy

39 (61.9)

18 (58.1)

.72

16 (64)

14 (56)

.56

Guideline-concordant treatment^a

42 (66.7)

12 (38.7)

.01*

16 (64)

8 (32)

.02*

Guideline discordant treatment:^a

21 (33.3)

19 (61.3)

.01*

9 (36)

17 (68)

.02*

 β-lactams without Q or M:

18 (28.6)

15 (48.4)

7 (28)

13 (52)

 Nonantipseudomonas β-lactams without Q or M

5 (7.9)

4 (12.9)

0

4 (16)

 Antipseudomonas β-lactams without Q or M

13 (20.6)

11 (35.5)

7 (28)

9 (36)

 Q without β-lactams

1 (1.6)

4 (12.9)

1 (4)

4 (16)

 M without β-lactams

2 (3.2)

0

1 (4)

0

Inadequate initial antibiotic treatment^b

7 (11.1)

4 (12.9)

1

5 (20)

4 (16)

1

Initial antibiotic regimen was modified

13 (20.6)

24 (77.4)

<.001*

7 (28)

19 (76)

.001*

Length of stay in hospital, d^c

9.9 ± 8.9

20.2 ± 11.1

.001*

13.5 ± 12.9

20.1 ± 12.1

.16

Hospital-free day, d^d

20.6 ± 5.6

4.8 ± 7.5

<.001*

18 ± 7.1

5.2 ± 8

<.001*